Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03935048 · ClinicalTrials.gov registry record · NA

Diet and Health in Adults With Metabolic Syndrome

A NA study of Metabolic Syndrome, sponsored by University of Arkansas, Fayetteville.

Active
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT03935048: Active NA study of Metabolic Syndrome, sponsored by University of Arkansas, Fayetteville.

NCT03935048 is a NA study of Metabolic Syndrome that is active but no longer recruiting, run by University of Arkansas, Fayetteville. The registered enrollment target is 90 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03935048, a NA study of Metabolic Syndrome, is active but no longer recruiting, sponsored by University of Arkansas, Fayetteville.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The prevalence of US adults with Metabolic Syndrome (MetS) is over 34%, impacting nearly 35% of all adults and 50% of those aged 60 years or older. MetS is characterized as a combination of underlying risk factors that when, occurring together, increase the risk for chronic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease, stroke, and certain types of cancer, resulting in an 1.6-fold increase in mortality. According the American Heart Association, health risks associated with Metabolic Syndrome can be significantly reduced by reducing body weight and eating a diet that is rich in whole grains, fruits, and vegetables. Potatoes (e.g. skin-on white potatoes) are an excellent source of potassium, vitamin C, and vitamin B6 and a good source of magnesium and dietary fiber. In addition, the potato has greater dry matter and protein per unit growing area compared with cereals. Despite this, consumers tend to believe that potatoes are high in calories and in fat compared with other carbohydrate sources such as rice or pasta, an incorrect assumption since a potato has negligible fat and a low energy density similar to legumes. Data from short-term nutrition intervention trials, suggest that potatoes consumed as part of a low-glycemic load meal can play a role in the prevention or treatment of MetS. However, the impact of long-term potato consumption on cardiometabolic risk factors associated with MetS is not known. Therefore, there is a critical need to determine if regular (\> 4 times per week) potato consumption can improve cardiometabolic health in individuals with MetS.

Primary Outcome

Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Free Fatty Acids, Triglycerides

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Higher protein, low glycemic load diet

Study Locations (1)

Arkansas

  • University of Arkansas - Fayetteville

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2019-06-01
Est. Completion 2025-12-30
Phase NA

What the registry record for NCT03935048 still lists

NCT03935048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Higher protein, low glycemic load diet is the first listed.

NCT03935048 reports a single indexed study location in Arkansas.

Frequently Asked Questions

What is clinical trial NCT03935048 about?

NCT03935048 is a clinical study titled "Diet and Health in Adults With Metabolic Syndrome". The prevalence of US adults with Metabolic Syndrome (MetS) is over 34%, impacting nearly 35% of all adults and 50% of those aged 60 years or older. MetS is characterized as a combination of underlying risk factors that when, occurring together, increase the risk for chronic diseases such as type 2 d...

What is the current status of trial NCT03935048?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2019-06-01. Estimated completion is 2025-12-30.

What conditions does trial NCT03935048 study?

This clinical trial studies the following conditions: Metabolic Syndrome.

What interventions are being tested in trial NCT03935048?

The interventions under investigation include: Higher protein, low glycemic load diet (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03935048?

This trial is sponsored by University of Arkansas, Fayetteville, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03935048 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03935048's enrollment target sits among peer trials

90 37th of 102 higher than 64 of 102 other Metabolic Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03935048, the US trial registry maintained by the National Library of Medicine. NCT03935048 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.